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Abstract Endoscopic scoring systems in Crohn’s disease and
ulcerative colitis aim to translate the assessment of mucosal
disease activity into a quantified value. This value seeks to
provide a clear, objective record of the endoscopic mucosal
severity, which can then be used to guide medical manage-
ment decisions. The primary driver of all endoscopic indices,
however, is to define a scale of responsiveness for therapeutic
endpoints in clinical trials. Mucosal healing now has wide-
spread acceptance as a therapeutic and clinical endpoint, but
despite the development of multiple endoscopic scoring sys-
tems, the endoscopic definition has yet to be resolved. This
review describes recent advances in endoscopic scoring sys-
tems for ulcerative colitis (Mayo Clinic endoscopy subscore,
UCEIS, and UCCIS among others) and for Crohn’s disease.
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Introduction
Endoscopic scoring systems of disease activity in inflamma-
tory bowel disease (IBD) have a pivotal role in assessment and
management. Scoring systems aim to interpret the endoscopic
disease appearance and translate this into a quantified score,
which introduces standardization and should reduce inter-
(and intra-) observer variability. This enables endoscopic end-
points for clinical trials to be defined and facilitates compari-
sons between trials. A secondary purpose of scoring systems
is their use in clinical practice, to guide therapeutic decisions,
and to use the scoring system of mucosal appearance as an
indicator of the course of the disease or longer term outcome.
Mucosal healing is now preferred over clinical remission as a
target endpoint [1•], because it has been demonstrated to re-
duce hospitalization and corticosteroid use, to reduce the risk
of colectomy or bowel resection, and to reduce the risk of
colorectal cancer [2]. It is also associated with sustained clin-
ical response and improved quality of life [2]. Mucosal
healing is not only a treatment target [3, 4••, 5, 6], but can also
delete guide adjustment of medical therapy [2]. Based on re-
peated endoscopic assessment of mucosal disease activity in
ulcerative colitis, medical therapy can be adjusted with a treat
to target approach [7] and this has been strongly associated
with achieving mucosal healing [8•]. The implication of mu-
cosal healing on clinical and therapeutic outcomes has lead to
endoscopic appearance being incorporated into primary end-
points in therapeutic trials. It is thus important to have robust,
validated scoring systems that enable reliable quantification
and interpretation of mucosal appearance.
Characteristics of Endoscopic Scoring Systems
The Use of Descriptors
The difficulty in describing the diverse mucosal appearance in
IBD has long been recognized. Attempts to develop specific
measures of disease activity has led to a plethora of scoring
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systems being developed for endoscopic disease activity, few
of which have undergone formal validation.
From the early stages of developing endoscopic scoring
systems, it was noted that discontinuous variables were essen-
tial to reduce inter-observer variability [9]. There are, howev-
er, numerous proposed descriptors including vascular pattern,
mucosal erythema, mucosal granularity, mucosal edema,
mucopurulent exudate, bleeding, incidental, and contact fria-
bility as well as erosions and ulcers. Mucosal friability has
been difficult to define and a source of disagreement between
central readers and site investigators in mild to moderate ul-
cerative colitis (UC) [10••], so newer systems of avoided this
descriptor. During the development of the Ulcerative Colitis
Endoscopic Index of Severity (UCEIS), the three descriptors
of vascular pattern, bleeding and erosions, or ulcers, were
found to account for 86 % of the variability in evaluation of
overall severity by visual analogue scale (VAS), which has
provided simple, pre-defined, and tested terms for describing
the mucosal appearance in ulcerative colitis.
Ease of Use
An endoscopic scoring system that is to bewidely used both in
clinical trials and clinical practice needs to be simple to use.
All indices require training to be used to best effect. The
Crohn’s Disease Endoscopic Index of Severity (CDEIS), for
example, although widely used in multiple clinical studies and
randomized controlled trials is complex, requires experience,
and is not commonly used in general endoscopic practice. The
CDEIS total score ranges from 0 to 44. The Simple
Endoscopic Score for Crohn’s Disease (SES-CD) was devel-
oped in response to the complexities of the CDEIS and uses
four descriptors each allocated to the five bowel segments.
Validation and Adequate Observer Variability
The strength of intra-observer or inter-observer agreement is
commonly evaluated according to the criteria of Landis and
Koch, whereby interclass correlation coefficients of <0.00,
0.00 to 0.20, 0.21 to 0.40, 0.41 to 0.60, 0.61 to 0.80, and
0.81 to 1.00 represent poor, slight, fair, moderate, substantial,
and almost perfect agreement, respectively [11].
A study (2014) has assessed the reproducibility of four
endoscopic scoring systems: Mayo subscore for ulcerative
colitis, Rutgeerts score for postoperative Crohn’s disease,
CDEIS, and SES-CD. Fourteen gastroenterologists experi-
enced in endoscopic scoring for IBD and 30 gastroenterolo-
gists who had not received specific training in endoscopic
scores reviewed 31 endoscopic videos of IBD. The Mayo
subscore demonstrated suboptimal agreement with a κ score
of 0.53 and 0.71 for the two groups. The Rutgeerts κ score for
experienced and inexperienced groups were 0.57 and 0.67.
Intra-class correlation coefficients (ICC) for the CDEIS were
0.83 and 0.67, and for SES-CD were 0.93 and 0.68 [12],
respectively. This inconsistency among gastroenterologists
in assessing endoscopic disease severity can result in varia-
tions in rates of response in therapeutic IBD trials that can
affect licensing [10••]. In a study of mesalamine in mild to
moderately active UC, there was substantial disagreement be-
tween site readers and central reader, with an ICC of 0.11 at
screening. This resulted in 31 % of patients enrolled being
considered ineligible by a central reader. Exclusion of these
patients substantially reduced the remission rate in the placebo
group [10••]. As a consequence of central reading, the clinical
trial outcome changed from one lacking significance to one
that was significant. In another study, central reading reduced
overall variability of scores, particularly in mild to moderate
endoscopic disease severity, represented by a UCEIS score of
between 3 and 5 [13]. These studies highlight two principles:
(i) Central reading in trials reduces variation in endoscopic
interpretation, and
(ii) The need to select a validated endoscopic scoring system
that has limited inter-observer variability.
These factors potentially influence the outcome of clinical
trials.
A further study (2014) assessed whether commonly used
disease activity indices for UC were reliable and clinically
relevant. One hundred consecutive patients with ulcerative
colitis presenting for review had clinical symptoms recorded
and a video sigmoidoscopy performed on the same day. The
Simple Clinical Colitis Activity, Mayo Clinic index, and Seo
indices were compared with an inter-observer agreement of
between κ 0.72 and 0.89 for the three indices; however, the
Mayo Clinic index had the greatest variation (κ=0.38) [14].
The UCEIS is the first validated tool for assessing endo-
scopic disease activity in ulcerative colitis and scores the
worst affected area at flexible sigmoidoscopy. Validation
was performed in a study where 25 investigators blinded to
clinical information assessed 28 videos using the descriptors
from the UCEIS and a VAS to assess overall severity. There
was high intra-investigator and inter-investigator reliability
ratios of 0.96 and 0.88, respectively [15••].
Current Updates in Scoring Indices in Ulcerative
Colitis
Clinical implications of endoscopic scoring systems are im-
portant to enable the meaningful application of the scores. The
impact of the knowledge of clinical information on endoscop-
ic scores has been studied (2015). In a study using a cohort of
independent central reader investigators, the knowledge or
absence of clinical information was found to have minimal
impact on mean UCEIS scores of sigmoidoscopies. Intra-
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reader κ scores for the full UCEIS were 0.51 and 0.56 for the
blinded and unblinded readers, respectively, which was not
significantly different (p=0.66) [13]. This study also found
the UCEIS to correlate well with contemporaneously recorded
symptoms. The Modified Baron Score correlated less well,
but no comparison could be made with the Mayo Clinic index
because patient-reported symptoms were derived from
subscores of that index [13]. The responsiveness of the
Modified Mayo Clinic Endoscopic Score, Modified Baron
Score, and UCEIS to clinical change have also been studied
in a randomized placebo-controlled trial of mesalamine ther-
apy. All three indices displayed similar responsiveness for
changes of UC disease activity, but the UCEIS was numeri-
cally better in all regards and the larger scale (0–8 compared to
0–3 in the Mayo Clinic endoscopy subscore) may have ad-
vantages in the evaluating response [16]. This has proved to
be the case in a Japanese study (2015) comparing the Mayo
Clinic and UCEIS endoscopy scores for detecting response to
treatment with tacrolimus: the UCEIS detected change over an
interval of 3 months, while the Mayo clinic score did not [17].
In acute severe colitis, the UCEIS helps predict outcomes.
A study of 89 consecutive causes of acute severe colitis ad-
mitted to a single institution were retrospectively reviewed,
and admission endoscopic disease severity by UCEIS found
to correlate with the outcome. The study suggested a strong
likelihood of needing rescue therapy with ciclosporin or
infliximab for a high UCEIS score; 11/14 (79 %) with a
UCEIS score ≥7 required rescue therapy. There was a signif-
icant association between UCEIS and colectomy, when the
UCEIS was ≥5, 33 % required colectomy compared to 9 %
≤4 (p=0.037) [18•].
Current scores for ulcerative colitis do not however, take
into account extent and distribution of mucosal inflammation,
and a Modified Mayo Endoscopic Score (MMES) has been
developed to address this (2015). Dividing the colon into five
segments, the Mayo endoscopic subscore for each segment is
added together to give a Modified Score. This Modified Score
is then multiplied by the maximal extent of inflammation then
divided by the number of segments with active inflammation
to give the MMES. The MMES correlates with clinical, bio-
logical, and histological activity, but has yet to be validated
[19•]. Extent, however, is another dimension to endoscopic
severity. It is relevant to assessing the overall severity of
UC, but so are systemic features (pulse rate, temperature, ane-
mia) and treatment responsiveness. For this reason, our belief
is that extent is best rated separately and not mixed with as-
sessment of endoscopic mucosal severity. This avoids adding
the complexity of segmental assessment to the endoscopic
evaluation of UC. Beware the CDEIS! The UCEIS evaluates
the worst-affected mucosa at flexible sigmoidoscopy [20].
Yet another dimension integral to endoscopy is the histo-
logical assessment of disease severity in mucosal biopsies.
Although historically endoscopically active UC does not
correlate well to histological severity, until now there have
been no validated scores to compare. Histological remission
in UC may yet have predictive value. In a post hoc analysis
comparing endoscopic assessment using the Rachmilewitz in-
dex and histological assessment, 52/380 (14 %) reported en-
doscopically active UC but no histological signs of active
inflammation at baseline. Of these patients, 48/52 (92 %)
reached clinical remission in a clinical trial, but it can be ar-
gued that the absence of histological disease activity meant
that they were in remission in the first place [21]. This dispar-
ity matters to the recruitment of patients to clinical trials test-
ing therapy for active UC. In contrast, histological remission
predicted outcome over a 6-year follow-up period with regard
to corticosteroid use and hospitalization with acute severe co-
litis, while endoscopic mucosal healing did not [22••].
Histologic endpoints may have a role as a surrogate marker
of long-term outcomes [23].
Current Updates in Scoring Indices in Crohn’s
Disease
The precision of the Rutgeerts score has recently been called
into question, although it has been used in clinical practice and
therapeutic trials since 1990. However, the Rutgeerts score has
not been prospectively validated and the definition of postop-
erative recurrence, commonly defined as a score of ≥i2, has
been questioned. In the POCER trial (2015), defining postop-
erative recurrence as a Rutgeerts score ≥i3 would have resulted
in a non-statistically significant difference between active care
and standard care arms [22••]. In another prospective, multicen-
ter trial which included patients with Crohn’s disease higher
risk of recurrence after ileocolic resection, patients were ran-
domized to systematic azathioprine ≤2 weeks from surgery, or
endoscopy-driven initiation of azathioprine for patients with a
Rutgeerts score ≥i2 at week 26 or 52 following surgery. No
significant difference was demonstrated in the primary end-
point of endoscopic remission (Rutgeerts score ≥i0-i1) at week
102 between the two groups, although the study was prema-
turely stopped due to slow recruitment [24•]. A third prospec-
tive study (PREVENT) of infliximab versus placebo for pa-
tients at high risk of recurrence after ileocolic resection and
anastomosis was stopped prematurely, because the event rate
(clinical relapse) was lower than predicted by endoscopy, al-
though the results have yet to be published. This calls into
question the value of the Rutgeerts score for clinical decision-
making, particularly the i2 subscore which groups lesions at the
anastomosis and neoterminal ileum together.
In an attempt to determine a definition for endoscopic re-
sponse and predict sustained clinical benefit, the SES-CD and
CDEIS scores from the SONIC trial were. After central
readers calculated scores at baseline and a subsequent endos-
copy after 26 weeks’ treatment with infliximab, azathioprine
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or both, endoscopic responsewas defined as a ≥50% decrease
from baseline in SES-CD or CDEIS. Endoscopic response at
26 weeks, according to this definition, was predictive of
corticosteroid-free clinical remission at week 50 [5].
Although this proposed cutoff appears to be a relevant end-
point, further validation and evaluation are required.
Conclusion
Endoscopic scoring systems are necessary for standardized
reporting of mucosal appearance in inflammatory bowel dis-
ease, both in clinical trials and practice. The UCEIS is emerg-
ing as a useful index with clinical and therapeutic relevance
that has been validated with good intra- and inter-observer
variability. How the UCEIS and Mayo Clinic endoscopic
score compare needs further study in prospective therapeutic
trials that are currently in progress, but data to date suggest an
advantage for the UCEIS. The Rutgeerts postoperative endo-
scopic score, although widely used, needs to be re-examined,
particularly the definition of the subscore of i2. Simplification
of endoscopic scoring systems for CD would increase their
value if the key components that predict outcomes (such as a
score at the most diseased area) could be defined. The clinical
relevance of endoscopic response to treatment, endoscopic
remission, and mucosal healing will remain elusive until there
is general accord on their definition.
Compliance with Ethical Standards
Conflict of Interest Shara Nguyen Ket reports grants from Shire, out-
side the submitted work. Rebecca Palmer declares no conflict of interest.
Simon Travis is on the governing board of ECCO, has received con-
sultancy fees from AbbVie, Centocor, Schering-Plough, Bristol Myers
Squibb, ChemoCentryx Inc, Cosmo Technologies, Elan Pharma Inc,
Genentech, Giuliani, Glenmark Pharma, Lilly, Merck and Co., NPS,
Otsuka Pharmaceuticals, PDL BioPharma, Pfizer Inc., Proximagen,
Shire Pharma, Synthon Pharma, Takeda, TopiVert, UCB, VHsquared,
Vifor, and Warner Chilcott. Simon Travis has also provided expert testi-
mony for Santarus, Inc., Cosmo Technologies, and Tillotts Pharma.
Professor Travis has received investigational grants from Ferring,
AbbVie, Schering-Plough, Merck Sharpe & Dome (MSD), Procter &
Gamble, Warner Chilcott, International Organisation of IBD, Lilly,
Norman Collison Foundation, UCB, and Vifor. Professor Travis has also
received payment for service on speakers’ bureau from Abbvie, Schering
Plough, Centocor, Merck and Co., Given Imaging, UCB Pharma, Ferring
Pharmaceuticals, Tillotts Laboratories, Shire, Sanofi Aventis, Vifor, and
Takeda. Professor Travis has also received payment for manuscript prep-
aration from Ferring and royalties from Wiley Blackwell, Elsevier, and
Oxford University Press as well as payment for development of educa-
tional presentations from Abbott Laboratories, Procter & Gamble, and
Warner Chilcott. Travel accommodations and expense reimbursement
have also been paid to Professor Travis from Abbvie and UEG,
Professor Travis is employed by the University of Oxford and Oxford
University Hospital and received part salary for a nurse involved in ther-
apeutic education with Schering Plough, MSD, Vifor, Abbott
Laboratories, and Procter & Gamble.
Professor Travis was the lead author in the development of the
UCEIS. The UCEIS© is freely available for use, acknowledging that
the copyright of the terminology is registered to Watson Laboratories,
NJ, successors in interest to Warner Chilcott Pharmaceuticals.
Human and Animal Rights and Informed Consent This article does
not contain any studies with animal subjects performed by any of the
authors. All studies on human subjects included informed consent, with
details published in the relevant papers.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1.• Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS,
et al. Disease activity assessment in IBD: clinical indices and bio-
markers fail to predict endoscopic remission. Inflamm Bowel Dis.
2015;21(4):824–31. Usefully evaluates clinical indices in
Crohn’s and UC as well as CRP and faecal calprotectin for
predicting endoscopic activity. Normal CRP and calprotectin
did not correlate wth endoscopic remission.
2. Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy
for colonic inflammatory bowel disease and methods to score dis-
ease activity. Gastrointest Endosc Clin N Am. 2014;24(3):367–78.
3. Sakuraba A, Annunziata ML, Cohen RD, Hanauer SB, Rubin DT.
Mucosal healing is associated with improved long-term outcome of
maintenance therapy with natalizumab in Crohn’s disease. Inflamm
Bowel Dis. 2013;19(12):2577–83.
4.•• Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K,
Colombel JF, et al. Adalimumab induces and maintains mucosal
healing in patients with Crohn’s disease: data from the EXTEND
trial. Gastroenterology. 2012;142(5):1102–11 e2. First clinical tri-
al with mucosal healing as a primary endpoint.
5. FerranteM, Colombel JF, SandbornWJ, ReinischW,Mantzaris GJ,
Kornbluth A, et al. Validation of endoscopic activity scores in pa-
tients with Crohn’s disease based on a post hoc analysis of data
from SONIC. Gastroenterology. 2013;145(5):978–86.e5.
6. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF,
Sandborn WJ, et al. Vedolizumab as induction and maintenance
therapy for ulcerative colitis. New Engl J Med. 2013;369(8):699–
710.
7. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ.
Feasibility of endoscopic assessment and treating to target to
achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis.
2014;20(2):231–9.
8.• Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ.
Endoscopic assessment and treating to target increase the likelihood
of mucosal healing in patients with Crohn’s disease. Clin
Gastroenterol H. 2014;12(6):978–85. Useful review.
9. Baron JH, Connell AM, Lennard-Jones JE. Variation between ob-
servers in describing mucosal appearances in proctocolitis. Brit
Med J. 1964;1(5375):89–92.
50 Page 4 of 5 Curr Gastroenterol Rep (2015) 17: 50
10.•• Feagan BG, Sandborn WJ, D’Haens G, Pola S, McDonald JW,
Rutgeerts P, et al. The role of centralized reading of endoscopy in
a randomized controlled trial of mesalamine for ulcerative colitis.
Gastroenterology. 2013;145(1):149–57 e2. Central reading of en-
doscopy scoring shown to impact the outcome of a therapeutic
clinical trial.
11. Landis JR, Koch GG. The measurement of observer agreement for
categorical data. Biometrics. 1977;33(1):159–74.
12. Daperno M, Comberlato M, Bossa F, Biancone L, Bonanomi AG,
Cassinotti A, et al. Inter-observer agreement in endoscopic scoring
systems: preliminary report of an ongoing study from the Italian
group for inflammatory bowel disease (IG-IBD). Dig Liver Dis.
2014;46(11):969–73.
13. Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer
SB et al. The impact of clinical information on the assessment of
endoscopic activity: characteristics of the ulcerative colitis endo-
scopic index of severity (UCEIS). J Crohns Colitis. 2015.
14. Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, et
al. Comparing disease activity indices in ulcerative colitis. J Crohns
Colitis. 2014;8(4):318–25.
15.•• Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel
JF, et al. Reliability and initial validation of the ulcerative colitis
endoscopic index of severity. Gastroenterology. 2013;145(5):987–
95. Description of the first validated endoscopic scoring system
for UC; a simple score (0–8) of three descriptors accounts for
86% of the variance between independent observers.
16. Levesque BG, Loftus EV, Panaccione R, McDonald JW, Van
Assche G, Zou G, et al. Responsiveness of endoscopic indices in
the evaluation of ulcerative colitis. J Crohns Colitis. 2014;8.
abstract.
17. Ikeya K, Hanai H, Sugimoto K, et al. The ulcerative colitis endo-
scopic index of severity more accurately reflects clinical outcomes
and long-term prognosis than the Mayo endoscopic score. J Crhns
Colitis (in press). 2015.
18.• Corte C, Fernandopulle N, Catuneanu AM, Burger D, Cesarini M,
White L, et al. Association between the ulcerative colitis endoscopic
index of severity (UCEIS) and outcomes in acute severe ulcerative
colitis. J Crohns Colitis. 2015;9(5):376–81. Predictive value of the
UCEIS in acute severe colitis.
19.• Lobaton T, Bessissow T, De Hertogh G, Lemmens B, Maedler C,
Van Assche G et al. Themodified mayo endoscopic score (MMES):
a new index for the assessment of extension and severity of endo-
scopic activity in ulcerative colitis patients. J Crohns Colitis. 2015.
Describes segmental assessment in UC.
20. Travis SPL, Corte C, Keshav S. Does disease extent matter when
scoring the UCEIS? J Crohns Colitis. 2015;9:694.
21. Wolff S, Terheggen G, Mueller R, Greinwald R, Franklin J, Kruis
W. Are endoscopic endpoints reliable in therapeutic trials of ulcer-
ative colitis? Inflamm Bowel Dis. 2013;19(12):2611–5.
22.•• Bryant RV, Burger DC, Delo J,Walsh AJ, Thomas S, von Herbay A
et al. Beyond endoscopic mucosal healing in UC: histological re-
mission better predicts corticosteroid use and hospitalisation over 6
years of follow-up. Gut. 2015.Describes the value of histopathol-
ogy beyond endoscopic scoring of remission for predicting out-
come in a cohort of patients followed for 6 years.
23. Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review:
histological remission in inflammatory bowel disease. Is ‘complete’
remission the new treatment paradigm? An IOIBD initiative. J
Crohns Colitis. 2014;8(12):1582–97.
24.• Ferrante M, Papamichael K, Duricova D, D’Haens G, Vermeire S,
Archavlis E et al. Systematic versus endoscopy-driven treatment
with azathioprine to prevent postoperative ileal Crohn’s disease
recurrence. J Crohns Colitis. 2015. Raises questions about the
precision of the Rutgeerts’ post-operative index and the poten-
tial need to refine the i2 endpoint.
Curr Gastroenterol Rep (2015) 17: 50 Page 5 of 5 50
